Role of Semaphorin 3A in Kidney Development and Diseases

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 Oct 14

PMID 37835781

Authors

Yizhen Sang

Kenji Tsuji

Hiroyuki Nakanoh

Kazuhiko Fukushima

Shinji Kitamura

Jun Wada

Affiliations

Soon will be listed here.

Abstract

Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is a secreted and membrane-associated protein, which regulates diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence has revealed that excess SEMA3A expression and the subsequent signaling pathway aggravate kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports have demonstrated that the inhibition of SEMA3A ameliorated kidney injury via a reduction in cell apoptosis, fibrosis and inflammation; thus, SEMA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized the current knowledge regarding the role of SEMA3A in kidney pathophysiology and their potential use in kidney diseases.

Citing Articles

Soluble Neuropilin-1 Is Elevated in Sepsis and Correlates with Organ Dysfunction and Long-Term Mortality in Critical Illness.

Hohlstein P, Schumacher E, Abu Jhaisha S, Adams J, Pollmanns M, Schneider C Int J Mol Sci. 2024; 25(10).

PMID: 38791476 PMC: 11121523. DOI: 10.3390/ijms25105438.

Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention.

Ali A, Khatoon A, Shao C, Murtaza B, Tanveer Q, Su Z RNA Biol. 2023; 21(1):1-18.

PMID: 38090817 PMC: 10761088. DOI: 10.1080/15476286.2023.2293335.

References

Prattichizzo F, de Candia P, Ceriello A . Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism. 2021; 120:154799. DOI: 10.1016/j.metabol.2021.154799. View

Reidy K, Aggarwal P, Jimenez J, Thomas D, Veron D, Tufro A . Excess podocyte semaphorin-3A leads to glomerular disease involving plexinA1-nephrin interaction. Am J Pathol. 2013; 183(4):1156-1168. PMC: 3791681. DOI: 10.1016/j.ajpath.2013.06.022. View

Iwano M, Plieth D, Danoff T, Xue C, Okada H, Neilson E . Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002; 110(3):341-50. PMC: 151091. DOI: 10.1172/JCI15518. View

Tian T, Chen L, Wang Z, Zhu M, Xu W, Wu B . Sema3A Drives Alternative Macrophage Activation in the Resolution of Periodontitis via PI3K/AKT/mTOR Signaling. Inflammation. 2023; 46(3):876-891. DOI: 10.1007/s10753-022-01777-z. View

Jacob S, Al-Kandari A, Alroughani R, Al-Temaimi R . Assessment of plasma biomarkers for their association with Multiple Sclerosis progression. J Neuroimmunol. 2017; 305:5-8. DOI: 10.1016/j.jneuroim.2017.01.008. View

Nitzan A, Corredor-Sanchez M, Galron R, Nahary L, Safrin M, Bruzel M . Inhibition of Sema-3A Promotes Cell Migration, Axonal Growth, and Retinal Ganglion Cell Survival. Transl Vis Sci Technol. 2021; 10(10):16. PMC: 8626852. DOI: 10.1167/tvst.10.10.16. View

Kurokawa S, Kashimoto M, Hagikura K, Shimodai-Yamada S, Otsuka N, Wakamatsu Y . Intravenous Semaphorin 3A Administration Maintains Cardiac Contractility and Improves Electrical Remodeling in a Mouse Model of Isoproterenol-Induced Heart Failure. Int Heart J. 2023; 64(3):453-461. DOI: 10.1536/ihj.22-705. View

Ivakhnitskaia E, Chin M, Siegel D, Guaiquil V . Vinaxanthone inhibits Semaphorin3A induced axonal growth cone collapse in embryonic neurons but fails to block its growth promoting effects on adult neurons. Sci Rep. 2021; 11(1):13019. PMC: 8217491. DOI: 10.1038/s41598-021-92375-w. View

Doi K, Noiri E, Nangaku M, Yahagi N, Jayakumar C, Ramesh G . Repulsive guidance cue semaphorin 3A in urine predicts the progression of acute kidney injury in adult patients from a mixed intensive care unit. Nephrol Dial Transplant. 2013; 29(1):73-80. PMC: 3888311. DOI: 10.1093/ndt/gft414. View

10.

Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E . Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev. 2011; 11(9):670-7. DOI: 10.1016/j.autrev.2011.11.018. View

11.

Reidy K, Villegas G, Teichman J, Veron D, Shen W, Jimenez J . Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development. Development. 2009; 136(23):3979-89. PMC: 2778745. DOI: 10.1242/dev.037267. View

12.

Jiang Z, Qian L, Yang R, Wu Y, Guo Y, Chen T . LncRNA TCF7 contributes to high glucose-induced damage in human podocytes by up-regulating SEMA3A via sponging miR-16-5p. J Diabetes Investig. 2022; 14(2):193-204. PMC: 9889678. DOI: 10.1111/jdi.13904. View

13.

Luo Y, Raible D, Raper J . Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell. 1993; 75(2):217-27. DOI: 10.1016/0092-8674(93)80064-l. View

14.

Gao H, Ma X, Guo Q, Xie L, Zhong Y, Zhang X . Expression of circulating Semaphorin3A and its association with inflammation and bone destruction in rheumatoid arthritis. Clin Rheumatol. 2018; 37(8):2073-2080. DOI: 10.1007/s10067-018-4070-x. View

15.

Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y . Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study. Nephrol Dial Transplant. 2022; 38(5):1204-1216. PMC: 10157761. DOI: 10.1093/ndt/gfac242. View

16.

Rimar D, Nov Y, Rosner I, Slobodin G, Rozenbaum M, Halasz K . Semaphorin 3A: an immunoregulator in systemic sclerosis. Rheumatol Int. 2015; 35(10):1625-30. DOI: 10.1007/s00296-015-3269-2. View

17.

Kar F, Hacioglu C, Senturk H, Donmez D, Kanbak G, Uslu S . Curcumin and LOXblock-1 ameliorate ischemia-reperfusion induced inflammation and acute kidney injury by suppressing the semaphorin-plexin pathway. Life Sci. 2020; 256:118016. DOI: 10.1016/j.lfs.2020.118016. View

18.

Florens N . Cardiorenal Syndrome: Ebony and Ivory. Diagnostics (Basel). 2023; 13(9). PMC: 10177396. DOI: 10.3390/diagnostics13091539. View

19.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

20.

Ranganathan P, Jayakumar C, Mohamed R, Weintraub N, Ramesh G . Semaphorin 3A inactivation suppresses ischemia-reperfusion-induced inflammation and acute kidney injury. Am J Physiol Renal Physiol. 2014; 307(2):F183-94. PMC: 4101625. DOI: 10.1152/ajprenal.00177.2014. View